Benefit of Treatment With Sebelipase-Alfa in a 63-Year-Old Patient With Advanced Liver and Atherosclerotic Disease Due to Lysosomal Acid Lipase Deficiency (LAL-D)

Am J Gastroenterol. 2018 Mar;113(3):443-445. doi: 10.1038/ajg.2017.486.

Authors

Elmar Aigner¹, Alexandra Feldman¹, Daniel Neureiter², Christian Datz³, Vlad Ratziu⁴, Bernhard Paulweber¹

Affiliations

¹ First Department of Medicine, Paracelsus Medical University Salzburg, Salzburg, Austria.
² Department of Pathology, Paracelsus Medical University Salzburg, Salzburg, Austria.
³ Department of Internal Medicine, Oberndorf Hospital, Salzburg, Austria.
⁴ Hospital Pitié-Salpêtrière, Institute of Cardiometabolism and Nutrition, Sorbonne Universités, Paris, France.

PMID: 29535442
DOI: 10.1038/ajg.2017.486

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Atherosclerosis / etiology
Carotid Stenosis / etiology
Cholesterol Ester Storage Disease / complications
Cholesterol Ester Storage Disease / drug therapy
Enzyme Replacement Therapy*
Esophageal and Gastric Varices / etiology
Female
Hepatomegaly / etiology
Humans
Hypertension, Portal / etiology
Liver Diseases / etiology
Middle Aged
Sterol Esterase / therapeutic use*
Treatment Outcome
Umbilical Veins
Wolman Disease / complications
Wolman Disease / drug therapy*

Substances

Sterol Esterase
Sebelipase alfa